{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:13:45Z","timestamp":1782548025668,"version":"3.54.5"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA007294"],"award-info":[{"award-number":["T32DA007294"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5R25DA035161"],"award-info":[{"award-number":["5R25DA035161"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40263-025-01168-6","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:52:04Z","timestamp":1740077524000},"page":"457-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["ADHD and Alcohol Use Disorder: Optimizing Screening and Treatment in Co-occurring Conditions"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2330","authenticated-orcid":false,"given":"Mariely","family":"Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4209-1329","authenticated-orcid":false,"given":"Frances R.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-9980","authenticated-orcid":false,"given":"Aimee N. C.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"2","key":"1168_CR1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/87565641.2010.549877","volume":"36","author":"RA Barkley","year":"2011","unstructured":"Barkley RA, Fischer M. Predicting impairment in major life activities and occupational functioning in hyperactive children as adults: self-reported executive function (EF) deficits versus EF tests. Dev Neuropsychol. 2011;36(2):137\u201361.","journal-title":"Dev Neuropsychol"},{"issue":"2","key":"1168_CR2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1176\/appi.ajp.2017.17030298","volume":"175","author":"MH Sibley","year":"2018","unstructured":"Sibley MH, et al. Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. Am J Psychiatry. 2018;175(2):140\u20139.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1168_CR3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.cpr.2011.01.006","volume":"31","author":"SS Lee","year":"2011","unstructured":"Lee SS, et al. Prospective association of childhood attention-deficit\/hyperactivity disorder (ADHD) and substance use and abuse\/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31(3):328\u201341.","journal-title":"Clin Psychol Rev"},{"issue":"2","key":"1168_CR4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1087054716629717","volume":"25","author":"S Chandra","year":"2021","unstructured":"Chandra S, Biederman J, Faraone SV. Assessing the validity of the age at onset criterion for diagnosing ADHD in DSM-5. J Atten Disord. 2021;25(2):143\u201353.","journal-title":"J Atten Disord"},{"key":"1168_CR5","unstructured":"Substance Abuse and Mental Health Services Administration, Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59). 2024, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration."},{"key":"1168_CR6","unstructured":"Substance Abuse and Mental Health Services Administration, Key substance use and mental health indicators in the United States: results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration., 2023."},{"issue":"2","key":"1168_CR7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1037\/adb0000542","volume":"34","author":"AL Howard","year":"2020","unstructured":"Howard AL, et al. Early substance use in the pathway from childhood attention-deficit\/hyperactivity disorder (ADHD) to young adult substance use: evidence of statistical mediation and substance specificity. Psychol Addict Behav. 2020;34(2):281\u201392.","journal-title":"Psychol Addict Behav"},{"key":"1168_CR8","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105209","volume":"151","author":"CA Hartman","year":"2023","unstructured":"Hartman CA, et al. Anxiety, mood, and substance use disorders in adult men and women with and without attention-deficit\/hyperactivity disorder: a substantive and methodological overview. Neurosci Biobehav Rev. 2023;151: 105209.","journal-title":"Neurosci Biobehav Rev"},{"key":"1168_CR9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.psychres.2016.10.071","volume":"246","author":"M Fats\u00e9as","year":"2016","unstructured":"Fats\u00e9as M, et al. Addiction severity pattern associated with adult and childhood attention deficit hyperactivity disorder (ADHD) in patients with addictions. Psychiatry Res. 2016;246:656\u201362.","journal-title":"Psychiatry Res"},{"issue":"2","key":"1168_CR10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/add.12370","volume":"109","author":"K van Emmerik-van Oortmerssen","year":"2014","unstructured":"van Emmerik-van Oortmerssen K, et al. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study. Addiction. 2014;109(2):262\u201372.","journal-title":"Addiction"},{"key":"1168_CR11","unstructured":"Brynte C et al. Treatments and treatment predictors in patients with substance use disorders and comorbid attention-deficit\/hyperactivity disorder: first results from the international naturalistic cohort study of ADHD and SUD (INCAS). J Clin Psychiatry, 2024;86(1)."},{"key":"1168_CR12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.neubiorev.2021.07.010","volume":"128","author":"M Luderer","year":"2021","unstructured":"Luderer M, et al. Alcohol use disorders and ADHD. Neurosci Biobehav Rev. 2021;128:648\u201360.","journal-title":"Neurosci Biobehav Rev"},{"key":"1168_CR13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jsat.2014.11.005","volume":"51","author":"B Bihlar Muld","year":"2015","unstructured":"Bihlar Muld B, et al. Long-term outcomes of pharmacologically treated versus non-treated adults with ADHD and substance use disorder: a naturalistic study. J Subst Abuse Treat. 2015;51:82\u201390.","journal-title":"J Subst Abuse Treat"},{"key":"1168_CR14","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2021.106832","volume":"117","author":"C Daigre","year":"2021","unstructured":"Daigre C, et al. Treatment retention and abstinence of patients with substance use disorders according to addiction severity and psychiatry comorbidity: a six-month follow-up study in an outpatient unit. Addict Behav. 2021;117: 106832.","journal-title":"Addict Behav"},{"key":"1168_CR15","doi-asserted-by":"crossref","unstructured":"Kast KA, Rao V, Wilens TE. Pharmacotherapy for attention-deficit\/hyperactivity disorder and retention in outpatient substance use disorder treatment: a retrospective cohort study. J Clin Psychiatry. 2021;82(2).","DOI":"10.4088\/JCP.20m13598"},{"issue":"1\u20132","key":"1168_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2011.12.007","volume":"122","author":"K van Emmerik-van Oortmerssen","year":"2012","unstructured":"van Emmerik-van Oortmerssen K, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012;122(1\u20132):11\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"1168_CR17","doi-asserted-by":"crossref","unstructured":"Rohner H et al. Prevalence of attention deficit hyperactivity disorder (ADHD) among substance use disorder (SUD) populations: meta-analysis. Int J Environ Res Public Health. 2023;20(2).","DOI":"10.3390\/ijerph20021275"},{"issue":"3","key":"1168_CR18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/add.12369","volume":"109","author":"M Konstenius","year":"2014","unstructured":"Konstenius M, et al. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction. 2014;109(3):440\u20139.","journal-title":"Addiction"},{"issue":"6","key":"1168_CR19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamapsychiatry.2015.41","volume":"72","author":"FR Levin","year":"2015","unstructured":"Levin FR, et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit\/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiat. 2015;72(6):593\u2013602.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"1168_CR20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/15374416.2017.1417860","volume":"47","author":"ML Danielson","year":"2018","unstructured":"Danielson ML, et al. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199\u2013212.","journal-title":"J Clin Child Adolesc Psychol"},{"issue":"2","key":"1168_CR21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ije\/dyt261","volume":"43","author":"GV Polanczyk","year":"2014","unstructured":"Polanczyk GV, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434\u201342.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"1168_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12402-016-0208-3","volume":"9","author":"J Fayyad","year":"2017","unstructured":"Fayyad J, et al. The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord. 2017;9(1):47\u201365.","journal-title":"Atten Defic Hyperact Disord"},{"issue":"3","key":"1168_CR23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s13311-012-0135-8","volume":"9","author":"EG Willcutt","year":"2012","unstructured":"Willcutt EG. The prevalence of DSM-IV attention-deficit\/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490\u20139.","journal-title":"Neurotherapeutics"},{"issue":"40","key":"1168_CR24","doi-asserted-by":"crossref","first-page":"890","DOI":"10.15585\/mmwr.mm7340a1","volume":"73","author":"BS Staley","year":"2024","unstructured":"Staley BS, et al. Attention-deficit\/hyperactivity disorder diagnosis, treatment, and telehealth use in adults\u2014National Center for Health Statistics Rapid Surveys System, United States, October-November 2023. MMWR Morb Mortal Wkly Rep. 2024;73(40):890\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1168_CR25","doi-asserted-by":"crossref","unstructured":"Mattingly G, Childress A. Clinical implications of attention-deficit\/hyperactivity disorder in adults: what new data on diagnostic trends, treatment barriers, and telehealth utilization tell us. J Clin Psychiatry. 2024;85(4).","DOI":"10.4088\/JCP.24com15592"},{"key":"1168_CR26","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (5th ed.). 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"7","key":"1168_CR27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jamapsychiatry.2016.0465","volume":"73","author":"JC Agnew-Blais","year":"2016","unstructured":"Agnew-Blais JC, et al. Evaluation of the persistence, remission, and emergence of attention-deficit\/hyperactivity disorder in young adulthood. JAMA Psychiat. 2016;73(7):713\u201320.","journal-title":"JAMA Psychiat"},{"key":"1168_CR28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.neubiorev.2021.01.022","volume":"128","author":"SV Faraone","year":"2021","unstructured":"Faraone SV, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789\u2013818.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"1168_CR29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jcpp.12855","volume":"59","author":"BSG Molina","year":"2018","unstructured":"Molina BSG, et al. Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study. J Child Psychol Psychiatry. 2018;59(6):692\u2013702.","journal-title":"J Child Psychol Psychiatry"},{"key":"1168_CR30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.drugalcdep.2017.11.011","volume":"184","author":"IJ Elkins","year":"2018","unstructured":"Elkins IJ, et al. Associations between childhood ADHD, gender, and adolescent alcohol and marijuana involvement: a causally informative design. Drug Alcohol Depend. 2018;184:33\u201341.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1168_CR31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0893-133X(01)00367-0","volume":"26","author":"FA Wagner","year":"2002","unstructured":"Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26(4):479\u201388.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1168_CR32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1087054710392536","volume":"16","author":"M Rooney","year":"2012","unstructured":"Rooney M, Chronis-Tuscano A, Yoon Y. Substance use in college students with ADHD. J Atten Disord. 2012;16(3):221\u201334.","journal-title":"J Atten Disord"},{"issue":"9","key":"1168_CR33","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/add.13398","volume":"111","author":"SL Pedersen","year":"2016","unstructured":"Pedersen SL, et al. The indirect effects of childhood attention deficit hyperactivity disorder on alcohol problems in adulthood through unique facets of impulsivity. Addiction. 2016;111(9):1582\u20139.","journal-title":"Addiction"},{"issue":"2","key":"1168_CR34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1037\/a0015418","volume":"17","author":"J Weafer","year":"2009","unstructured":"Weafer J, Fillmore MT, Milich R. Increased sensitivity to the disinhibiting effects of alcohol in adults with ADHD. Exp Clin Psychopharmacol. 2009;17(2):113\u201321.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"13","key":"1168_CR35","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1177\/1087054720940417","volume":"25","author":"GCC Hong","year":"2021","unstructured":"Hong GCC, et al. Diet, physical activity, and screen time to sleep better: multiple mediation analysis of lifestyle factors in school-aged children with and without attention deficit hyperactivity disorder. J Atten Disord. 2021;25(13):1847\u201358.","journal-title":"J Atten Disord"},{"issue":"4\u20135","key":"1168_CR36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000508870","volume":"26","author":"G Van de Glind","year":"2020","unstructured":"Van de Glind G, et al. The international collaboration on ADHD and substance abuse (ICASA): mission, results, and future activities. Eur Addict Res. 2020;26(4\u20135):173\u20138.","journal-title":"Eur Addict Res"},{"issue":"1","key":"1168_CR37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s12888-022-04259-6","volume":"22","author":"C Brynte","year":"2022","unstructured":"Brynte C, et al. The clinical course of comorbid substance use disorder and attention deficit\/hyperactivity disorder: protocol and clinical characteristics of the INCAS study. BMC Psychiatry. 2022;22(1):625.","journal-title":"BMC Psychiatry"},{"key":"1168_CR38","doi-asserted-by":"crossref","unstructured":"Mariani, J.J. and F.R. Levin, Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict. 2007;16(Suppl 1):45\u201354 (quiz 55\u20136).","DOI":"10.1080\/10550490601082783"},{"key":"1168_CR39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.drugalcdep.2018.11.020","volume":"195","author":"M Luderer","year":"2019","unstructured":"Luderer M, et al. Screening for adult attention-deficit\/hyperactivity disorder in alcohol dependent patients: underreporting of ADHD symptoms in self-report scales. Drug Alcohol Depend. 2019;195:52\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1168_CR40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000487767","volume":"24","author":"CL Crunelle","year":"2018","unstructured":"Crunelle CL, et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit\/hyperactivity disorder. Eur Addict Res. 2018;24(1):43\u201351.","journal-title":"Eur Addict Res"},{"issue":"3","key":"1168_CR41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/15504263.2014.926691","volume":"10","author":"F Matthys","year":"2014","unstructured":"Matthys F, et al. Barriers to implementation of treatment guidelines for ADHD in adults with substance use disorder. J Dual Diagn. 2014;10(3):130\u20138.","journal-title":"J Dual Diagn"},{"issue":"2","key":"1168_CR42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/1874473708666150916112913","volume":"8","author":"S Ortal","year":"2015","unstructured":"Ortal S, et al. The role of different aspects of impulsivity as independent risk factors for substance use disorders in patients with ADHD: a review. Curr Drug Abuse Rev. 2015;8(2):119\u201333.","journal-title":"Curr Drug Abuse Rev"},{"issue":"1","key":"1168_CR43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/acer.13538","volume":"42","author":"AM Daurio","year":"2018","unstructured":"Daurio AM, et al. Impulsive personality traits mediate the relationship between adult attention-deficit\/hyperactivity symptoms and alcohol dependence severity. Alcohol Clin Exp Res. 2018;42(1):173\u201383.","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"1168_CR44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.drugalcdep.2013.04.010","volume":"132","author":"G van de Glind","year":"2013","unstructured":"van de Glind G, et al. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug Alcohol Depend. 2013;132(3):587\u201396.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1168_CR45","first-page":"467","volume":"119","author":"E Abdelnour","year":"2022","unstructured":"Abdelnour E, Jansen MO, Gold JA. ADHD diagnostic trends: increased recognition or overdiagnosis? Mo Med. 2022;119(5):467\u201373.","journal-title":"Mo Med"},{"key":"1168_CR46","unstructured":"American Psychiatric Association, Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 2000, Washington, DC: American Psychiatric Association."},{"issue":"5","key":"1168_CR47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2217\/npy.13.59","volume":"3","author":"JN Epstein","year":"2013","unstructured":"Epstein JN, Loren RE. Changes in the definition of ADHD in DSM-5: subtle but important. Neuropsychiatry (London). 2013;3(5):455\u20138.","journal-title":"Neuropsychiatry (London)"},{"issue":"1","key":"1168_CR48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/10870547231197242","volume":"28","author":"D Pham","year":"2024","unstructured":"Pham D, et al. ADHD diagnosis in children of non-US-born parents: a cross-sectional analysis. J Atten Disord. 2024;28(1):3\u201313.","journal-title":"J Atten Disord"},{"issue":"11","key":"1168_CR49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.14344","volume":"2","author":"W Chung","year":"2019","unstructured":"Chung W, et al. Trends in the prevalence and incidence of attention-deficit\/hyperactivity disorder among adults and children of different racial and ethnic groups. JAMA Netw Open. 2019;2(11): e1914344.","journal-title":"JAMA Netw Open"},{"key":"1168_CR50","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpr.2024.102461","volume":"112","author":"BM Merrill","year":"2024","unstructured":"Merrill BM, et al. Diversity and representation in ADHD psychosocial treatment research: a comprehensive synthesis with data from over 10,000 participants. Clin Psychol Rev. 2024;112: 102461.","journal-title":"Clin Psychol Rev"},{"issue":"1","key":"1168_CR51","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12888-020-02707-9","volume":"20","author":"S Young","year":"2020","unstructured":"Young S, et al. Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit\/ hyperactivity disorder in girls and women. BMC Psychiatry. 2020;20(1):404.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"1168_CR52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1108\/IJPH-03-2021-0020","volume":"18","author":"E Chaplin","year":"2022","unstructured":"Chaplin E, et al. Prisoners with attention deficit hyperactivity disorder: co-morbidities and service pathways. Int J Prison Health. 2022;18(3):245\u201358.","journal-title":"Int J Prison Health"},{"issue":"12","key":"1168_CR53","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1177\/1087054715598841","volume":"23","author":"C Roncero","year":"2019","unstructured":"Roncero C, et al. Psychiatric comorbidity in treatment-seeking alcohol dependence patients with and without ADHD. J Atten Disord. 2019;23(12):1497\u2013504.","journal-title":"J Atten Disord"},{"issue":"2","key":"1168_CR54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S0033291704002892","volume":"35","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245\u201356.","journal-title":"Psychol Med"},{"key":"1168_CR55","doi-asserted-by":"crossref","first-page":"34833","DOI":"10.1038\/srep34833","volume":"6","author":"R Shoham","year":"2016","unstructured":"Shoham R, et al. ADHD-associated risk taking is linked to exaggerated views of the benefits of positive outcomes. Sci Rep. 2016;6:34833.","journal-title":"Sci Rep"},{"key":"1168_CR56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drugalcdep.2017.07.039","volume":"180","author":"K van Emmerik-van Oortmerssen","year":"2017","unstructured":"van Emmerik-van Oortmerssen K, et al. Diagnosing ADHD during active substance use: feasible or flawed? Drug Alcohol Depend. 2017;180:371\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"1168_CR57","first-page":"96","volume":"6","author":"E Hagen","year":"2017","unstructured":"Hagen E, et al. One-year abstinence improves ADHD symptoms among patients with polysubstance use disorder. Addict Behav Rep. 2017;6:96\u2013101.","journal-title":"Addict Behav Rep"},{"key":"1168_CR58","doi-asserted-by":"crossref","unstructured":"Morgan, P.L. and E.H. Hu, Sociodemographic disparities in ADHD diagnosis and treatment among U.S. elementary schoolchildren. Psychiatry Res. 2023;327:115393.","DOI":"10.1016\/j.psychres.2023.115393"},{"key":"1168_CR59","doi-asserted-by":"crossref","unstructured":"Coker TR et al. Racial and ethnic disparities in ADHD diagnosis and treatment. Pediatrics. 2016;138(3).","DOI":"10.1542\/peds.2016-0407"},{"issue":"14","key":"1168_CR60","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1177\/1087054720951865","volume":"25","author":"MV Solanto","year":"2021","unstructured":"Solanto MV, Scheres A. Feasibility, acceptability, and effectiveness of a new cognitive-behavioral intervention for college students with ADHD. J Atten Disord. 2021;25(14):2068\u201382.","journal-title":"J Atten Disord"},{"issue":"3","key":"1168_CR61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/papt.12455","volume":"96","author":"CI Liu","year":"2023","unstructured":"Liu CI, et al. Effectiveness of cognitive behavioural-based interventions for adults with attention-deficit\/hyperactivity disorder extends beyond core symptoms: a meta-analysis of randomized controlled trials. Psychol Psychother. 2023;96(3):543\u201359.","journal-title":"Psychol Psychother"},{"issue":"10","key":"1168_CR62","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s10802-020-00675-y","volume":"48","author":"FL Wang","year":"2020","unstructured":"Wang FL, et al. Heterogeneous trajectories of problematic alcohol use, depressive symptoms, and their co-occurrence in young adults with and without childhood ADHD. J Abnorm Child Psychol. 2020;48(10):1265\u201377.","journal-title":"J Abnorm Child Psychol"},{"issue":"10","key":"1168_CR63","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jama.2024.0851","volume":"331","author":"L Li","year":"2024","unstructured":"Li L, et al. ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA. 2024;331(10):850\u201360.","journal-title":"JAMA"},{"issue":"1","key":"1168_CR64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S2215-0366(23)00332-2","volume":"11","author":"I Brikell","year":"2024","unstructured":"Brikell I, et al. ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases. Lancet Psychiatry. 2024;11(1):16\u201326.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"1168_CR65","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jadohealth.2021.04.025","volume":"69","author":"K Rao","year":"2021","unstructured":"Rao K, Carpenter DM, Campbell CI. Attention-deficit\/hyperactivity disorder medication adherence in the transition to adulthood: associated adverse outcomes for females and other disparities. J Adolesc Health. 2021;69(5):806\u201314.","journal-title":"J Adolesc Health"},{"issue":"6","key":"1168_CR66","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jadohealth.2016.12.011","volume":"60","author":"MR Schaefer","year":"2017","unstructured":"Schaefer MR, et al. Adherence to attention-deficit\/hyperactivity disorder medication during the transition to college. J Adolesc Health. 2017;60(6):706\u201313.","journal-title":"J Adolesc Health"},{"issue":"1","key":"1168_CR67","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/DBP.0000000000000723","volume":"41","author":"ST Wagoner","year":"2020","unstructured":"Wagoner ST, et al. Barriers to treatment adherence among college students with attention-deficit\/hyperactivity disorder. J Dev Behav Pediatr. 2020;41(1):9\u201315.","journal-title":"J Dev Behav Pediatr"},{"key":"1168_CR68","doi-asserted-by":"crossref","unstructured":"Khan, M.U. and P. Aslani, Exploring factors influencing initiation, implementation and discontinuation of medications in adults with ADHD. Health Expect. 2021;24(Suppl 1):82\u201394.","DOI":"10.1111\/hex.13031"},{"issue":"4","key":"1168_CR69","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s10597-016-0078-3","volume":"53","author":"B Sleath","year":"2017","unstructured":"Sleath B, et al. Youth views on communication about ADHD and medication adherence. Community Ment Health J. 2017;53(4):438\u201344.","journal-title":"Community Ment Health J"},{"issue":"5","key":"1168_CR70","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jadohealth.2018.05.033","volume":"63","author":"MR Schaefer","year":"2018","unstructured":"Schaefer MR, et al. Parent perceptions of their college students\u2019 self-management of attention-deficit\/hyperactivity disorder. J Adolesc Health. 2018;63(5):636\u201342.","journal-title":"J Adolesc Health"},{"issue":"5","key":"1168_CR71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3810\/pgm.2012.09.2591","volume":"124","author":"CB Montano","year":"2012","unstructured":"Montano CB, Young J. Discontinuity in the transition from pediatric to adult health care for patients with attention-deficit\/hyperactivity disorder. Postgrad Med. 2012;124(5):23\u201332.","journal-title":"Postgrad Med"},{"issue":"12","key":"1168_CR72","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/archgenpsychiatry.2012.271","volume":"69","author":"RG Klein","year":"2012","unstructured":"Klein RG, et al. Clinical and functional outcome of childhood attention-deficit\/hyperactivity disorder 33 years later. Arch Gen Psychiatry. 2012;69(12):1295\u2013303.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"1168_CR73","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/00325481.2019.1647080","volume":"131","author":"LA Adler","year":"2019","unstructured":"Adler LA, et al. Healthcare provider perspectives on diagnosing and treating adults with attention-deficit\/hyperactivity disorder. Postgrad Med. 2019;131(7):461\u201372.","journal-title":"Postgrad Med"},{"key":"1168_CR74","unstructured":"Health Resources and Services Administration (HRSA), Designated health professional shortage areas statistics, U.S.D.o.H.H. Services, Editor. 2025."},{"key":"1168_CR75","doi-asserted-by":"crossref","unstructured":"Wolraich ML et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4).","DOI":"10.1542\/peds.2019-2528"},{"key":"1168_CR76","doi-asserted-by":"crossref","unstructured":"Wolraich ML, Allan HJC, et al. AAP Subcommittee On Children And Adolescents with Attention-Deficit\/Hyperactive Disorder., Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):15.","DOI":"10.1542\/peds.2019-2528"},{"issue":"8","key":"1168_CR77","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/10870547241238899","volume":"28","author":"ML Danielson","year":"2024","unstructured":"Danielson ML, et al. Who provides outpatient clinical care for adults with ADHD? analysis of healthcare claims by types of providers among private insurance and medicaid enrollees, 2021. J Atten Disord. 2024;28(8):1225\u201335.","journal-title":"J Atten Disord"},{"issue":"5","key":"1168_CR78","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10488-019-00937-y","volume":"46","author":"SC Blake","year":"2019","unstructured":"Blake SC, et al. Prior authorization policies and preferred drug lists in medicaid plans: stakeholder perspectives on the implications for youth with ADHD. Adm Policy Ment Health. 2019;46(5):580\u201395.","journal-title":"Adm Policy Ment Health"},{"issue":"45","key":"1168_CR79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19450","volume":"19","author":"M Richardson","year":"2015","unstructured":"Richardson M, et al. Non-pharmacological interventions for attention-deficit\/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research. Health Technol Assess. 2015;19(45):1\u2013470.","journal-title":"Health Technol Assess"},{"issue":"10","key":"1168_CR80","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jpepsy\/jsae060","volume":"49","author":"S Chung","year":"2024","unstructured":"Chung S, et al. Feasibility study of a telehealth school-based behavioral parent training group program for attention-deficit\/hyperactivity disorder. J Pediatr Psychol. 2024;49(10):700\u20139.","journal-title":"J Pediatr Psychol"},{"key":"1168_CR81","volume":"168","author":"SM Margherio","year":"2025","unstructured":"Margherio SM, et al. Effects on alcohol and substance use of a school-based training intervention for adolescents with ADHD. J Subst Use Addict Treat. 2025;168: 209523.","journal-title":"J Subst Use Addict Treat"},{"issue":"8","key":"1168_CR82","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00787-018-1256-3","volume":"28","author":"B French","year":"2019","unstructured":"French B, Sayal K, Daley D. Barriers and facilitators to understanding of ADHD in primary care: a mixed-method systematic review. Eur Child Adolesc Psychiatry. 2019;28(8):1037\u201364.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"6","key":"1168_CR83","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11121-020-01105-7","volume":"22","author":"MH Sibley","year":"2021","unstructured":"Sibley MH, et al. Implementing parent-teen motivational interviewing + behavior therapy for ADHD in community mental health. Prev Sci. 2021;22(6):701\u201311.","journal-title":"Prev Sci"},{"issue":"2","key":"1168_CR84","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.beth.2023.08.001","volume":"55","author":"PA Graziano","year":"2024","unstructured":"Graziano PA, et al. Community-delivered evidence-based practice and usual care for adolescent attention-deficit\/hyperactivity disorder: examining mechanistic outcomes. Behav Ther. 2024;55(2):412\u201328.","journal-title":"Behav Ther"},{"issue":"10","key":"1168_CR85","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3928\/00485713-20230911-04","volume":"53","author":"A Childress","year":"2023","unstructured":"Childress A, et al. Guidelines in the United States for the diagnosis and treatment of attention-deficit\/hyperactivity disorder in adults: why they are needed. Psychiatr Ann. 2023;53(10):461\u20139.","journal-title":"Psychiatr Ann"},{"issue":"8","key":"1168_CR86","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, et al. Use of medications for alcohol use disorder in the US: results From the 2019 National Survey on Drug Use and Health. JAMA Psychiat. 2021;78(8):922\u20134.","journal-title":"JAMA Psychiat"},{"key":"1168_CR87","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsat.2015.09.006","volume":"61","author":"MA Priester","year":"2016","unstructured":"Priester MA, et al. Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review. J Subst Abuse Treat. 2016;61:47\u201359.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1168_CR88","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13722-019-0151-7","volume":"14","author":"HJ Hagedorn","year":"2019","unstructured":"Hagedorn HJ, et al. Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes. Addict Sci Clin Pract. 2019;14(1):24.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"1168_CR89","doi-asserted-by":"crossref","first-page":"07","DOI":"10.35946\/arcr.v41.1.07","volume":"41","author":"BJ Mason","year":"2021","unstructured":"Mason BJ, Heyser CJ. Alcohol use disorder: the role of medication in recovery. Alcohol Res. 2021;41(1):07.","journal-title":"Alcohol Res"},{"key":"1168_CR90","doi-asserted-by":"crossref","unstructured":"Dguzeh U et al. Alcoholism: a multi-systemic cellular insult to organs. Int J Environ Res Public Health. 2018;15(6).","DOI":"10.3390\/ijerph15061083"},{"issue":"1\u20132","key":"1168_CR91","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.drugalcdep.2008.02.009","volume":"96","author":"TE Wilens","year":"2008","unstructured":"Wilens TE, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96(1\u20132):145\u201354.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"1168_CR92","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/14737175.2024.2370346","volume":"24","author":"GE Brancati","year":"2024","unstructured":"Brancati GE, et al. Current nonstimulant medications for adults with attention-deficit\/hyperactivity disorder. Expert Rev Neurother. 2024;24(8):743\u201359.","journal-title":"Expert Rev Neurother"},{"key":"1168_CR93","doi-asserted-by":"crossref","unstructured":"Spencer TJ et al. The mixed opioid receptor antagonist naltrexone mitigates stimulant-induced euphoria: a double-blind, placebo-controlled trial of naltrexone. J Clin Psychiatry. 2018;79(2).","DOI":"10.4088\/JCP.17m11609"},{"issue":"1","key":"1168_CR94","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/eb-2016-102415","volume":"20","author":"F De Crescenzo","year":"2017","unstructured":"De Crescenzo F, et al. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review. Evid Based Ment Health. 2017;20(1):4\u201311.","journal-title":"Evid Based Ment Health"},{"issue":"6","key":"1168_CR95","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2352-4642(22)00381-9","volume":"7","author":"MH Sibley","year":"2023","unstructured":"Sibley MH, et al. Non-pharmacological interventions for attention-deficit hyperactivity disorder in children and adolescents. Lancet Child Adolesc Health. 2023;7(6):415\u201328.","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"1168_CR96","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1176\/appi.ajp.2017.16060686","volume":"174","author":"PD Quinn","year":"2017","unstructured":"Quinn PD, et al. ADHD medication and substance-related problems. Am J Psychiatry. 2017;174(9):877\u201385.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1168_CR97","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euroneuro.2013.11.003","volume":"24","author":"HC Steinhausen","year":"2014","unstructured":"Steinhausen HC, Bisgaard C. Substance use disorders in association with attention-deficit\/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample. Eur Neuropsychopharmacol. 2014;24(2):232\u201341.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"1168_CR98","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.biopsych.2019.04.009","volume":"86","author":"Z Chang","year":"2019","unstructured":"Chang Z, et al. Risks and benefits of attention-deficit\/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry. 2019;86(5):335\u201343.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"1168_CR99","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaac.2018.11.014","volume":"58","author":"A Jangmo","year":"2019","unstructured":"Jangmo A, et al. Attention-deficit\/hyperactivity disorder, school performance, and effect of medication. J Am Acad Child Adolesc Psychiatry. 2019;58(4):423\u201332.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"1168_CR100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","volume":"175","author":"VI Reus","year":"2018","unstructured":"Reus VI, et al. The American Psychiatric Association Practice Guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86\u201390.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1168_CR101","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","volume":"82","author":"EM Burnette","year":"2022","unstructured":"Burnette EM, et al. Novel agents for the pharmacological treatment of alcohol use disorder. Drugs. 2022;82(3):251\u201374.","journal-title":"Drugs"},{"key":"1168_CR102","first-page":"1543","volume":"10","author":"K Gajria","year":"2014","unstructured":"Gajria K, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit\/hyperactivity disorder\u2014a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543\u201369.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"1168_CR103","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1176\/appi.ajp.2021.21010032","volume":"179","author":"MH Sibley","year":"2022","unstructured":"Sibley MH, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. Am J Psychiatry. 2022;179(2):142\u201351.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1168_CR104","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1176\/appi.ps.201800515","volume":"70","author":"J Biederman","year":"2019","unstructured":"Biederman J, et al. Evidence of low adherence to stimulant medication among children and youths with ADHD: an electronic health records study. Psychiatr Serv. 2019;70(10):874\u201380.","journal-title":"Psychiatr Serv"},{"key":"1168_CR105","doi-asserted-by":"crossref","unstructured":"Treuer T et al. Lost in transition: a review of the unmet need of patients with attention deficit\/hyperactivity disorder transitioning to adulthood. Asia Pac Psychiatry. 2017;9(2).","DOI":"10.1111\/appy.12254"},{"issue":"4","key":"1168_CR106","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/JCP.0000000000001055","volume":"39","author":"J Biederman","year":"2019","unstructured":"Biederman J, et al. A novel text message intervention to improve adherence to stimulants in adults with attention deficit\/hyperactivity disorder. J Clin Psychopharmacol. 2019;39(4):351\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"1168_CR107","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727\u201338.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"1168_CR108","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14656566.2023.2169604","volume":"24","author":"S Cortese","year":"2023","unstructured":"Cortese S. Evidence-based prescribing of medications for ADHD: where are we in 2023? Expert Opin Pharmacother. 2023;24(4):425\u201334.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1168_CR109","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1017\/S1092852919001822","volume":"26","author":"GW Mattingly","year":"2021","unstructured":"Mattingly GW, et al. Individualization of attention-deficit\/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions. CNS Spectr. 2021;26(3):202\u201321.","journal-title":"CNS Spectr"},{"issue":"10","key":"1168_CR110","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s40263-021-00848-3","volume":"35","author":"S Cortese","year":"2021","unstructured":"Cortese S, Newcorn JH, Coghill D. A practical, evidence-informed approach to managing stimulant-refractory attention deficit hyperactivity disorder (ADHD). CNS Drugs. 2021;35(10):1035\u201351.","journal-title":"CNS Drugs"},{"issue":"2","key":"1168_CR111","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12402-017-0242-9","volume":"10","author":"MD Weiss","year":"2018","unstructured":"Weiss MD, Surman CBH, Elbe D. Stimulant \u2018rapid metabolizers\u2019: wrong label, real phenomena. Atten Defic Hyperact Disord. 2018;10(2):113\u20138.","journal-title":"Atten Defic Hyperact Disord"},{"issue":"1","key":"1168_CR112","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/jcpp.13807","volume":"65","author":"SE McCabe","year":"2024","unstructured":"McCabe SE, et al. Is age of onset and duration of stimulant therapy for ADHD associated with cocaine, methamphetamine, and prescription stimulant misuse? J Child Psychol Psychiatry. 2024;65(1):100\u201311.","journal-title":"J Child Psychol Psychiatry"},{"issue":"9","key":"1168_CR113","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamapsychiatry.2023.2157","volume":"80","author":"BSG Molina","year":"2023","unstructured":"Molina BSG, et al. Association between stimulant treatment and substance use through adolescence into early adulthood. JAMA Psychiat. 2023;80(9):933\u201341.","journal-title":"JAMA Psychiat"},{"key":"1168_CR114","doi-asserted-by":"crossref","unstructured":"Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5(9):eaax4043.","DOI":"10.1126\/sciadv.aax4043"},{"key":"1168_CR115","doi-asserted-by":"crossref","unstructured":"Veliz PT et al. Trends in diversion sources for prescription stimulant misuse in U.S. adolescents. Am J Prev Med. 2023;65(3):543\u2013546.","DOI":"10.1016\/j.amepre.2023.03.018"},{"issue":"4","key":"1168_CR116","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1300\/J069v23n04_03","volume":"23","author":"SM Gordon","year":"2004","unstructured":"Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence. J Addict Dis. 2004;23(4):31\u201340.","journal-title":"J Addict Dis"},{"issue":"6","key":"1168_CR117","volume":"3","author":"LA Ray","year":"2020","unstructured":"Ray LA, et al. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(6): e208279.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1168_CR118","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1037\/0022-006X.75.4.663","volume":"75","author":"KB Carey","year":"2007","unstructured":"Carey KB, et al. Which heavy drinking college students benefit from a brief motivational intervention? J Consult Clin Psychol. 2007;75(4):663\u20139.","journal-title":"J Consult Clin Psychol"},{"issue":"8","key":"1168_CR119","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1080\/08870446.2017.1325889","volume":"32","author":"E Kuntsche","year":"2017","unstructured":"Kuntsche E, et al. Binge drinking: health impact, prevalence, correlates and interventions. Psychol Health. 2017;32(8):976\u20131017.","journal-title":"Psychol Health"},{"issue":"4","key":"1168_CR120","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1037\/0893-164X.18.4.390","volume":"18","author":"MP Martens","year":"2004","unstructured":"Martens MP, et al. Protective behavioral strategies when drinking alcohol and their relationship to negative alcohol-related consequences in college students. Psychol Addict Behav. 2004;18(4):390\u20133.","journal-title":"Psychol Addict Behav"},{"issue":"1","key":"1168_CR121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1037\/ccp0000553","volume":"89","author":"AD Anastopoulos","year":"2021","unstructured":"Anastopoulos AD, et al. A randomized controlled trial examining CBT for college students with ADHD. J Consult Clin Psychol. 2021;89(1):21\u201333.","journal-title":"J Consult Clin Psychol"},{"issue":"4","key":"1168_CR122","doi-asserted-by":"crossref","first-page":"625","DOI":"10.15288\/jsad.2012.73.625","volume":"73","author":"CI Rupp","year":"2012","unstructured":"Rupp CI, et al. Cognitive remediation therapy during treatment for alcohol dependence. J Stud Alcohol Drugs. 2012;73(4):625\u201334.","journal-title":"J Stud Alcohol Drugs"},{"key":"1168_CR123","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2019.106228","volume":"103","author":"K van Emmerik-van Oortmerssen","year":"2020","unstructured":"van Emmerik-van Oortmerssen K, et al. Prediction of drop-out and outcome in integrated cognitive behavioral therapy for ADHD and SUD: results from a randomized clinical trial. Addict Behav. 2020;103: 106228.","journal-title":"Addict Behav"},{"key":"1168_CR124","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.drugalcdep.2018.12.023","volume":"197","author":"K van Emmerik-van Oortmerssen","year":"2019","unstructured":"van Emmerik-van Oortmerssen K, et al. Integrated cognitive behavioral therapy for ADHD in adult substance use disorder patients: results of a randomized clinical trial. Drug Alcohol Depend. 2019;197:28\u201336.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"1168_CR125","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jts.23049","volume":"37","author":"SE Back","year":"2024","unstructured":"Back SE, et al. State of the science: treatment of comorbid posttraumatic stress disorder and substance use disorders. J Trauma Stress. 2024;37(6):803\u201313.","journal-title":"J Trauma Stress"},{"issue":"8","key":"1168_CR126","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00213-020-05563-3","volume":"237","author":"VS Tardelli","year":"2020","unstructured":"Tardelli VS, et al. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology. 2020;237(8):2233\u201355.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1168_CR127","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1080\/00952990.2021.1885677","volume":"47","author":"JJ Mariani","year":"2021","unstructured":"Mariani JJ, et al. Open-label pilot study of lisdexamfetamine for cocaine use disorder. Am J Drug Alcohol Abuse. 2021;47(3):402\u20139.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"8","key":"1168_CR128","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/ajad.12467","volume":"25","author":"DP Notzon","year":"2016","unstructured":"Notzon DP, et al. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit\/hyperactivity disorder and cocaine dependence. Am J Addict. 2016;25(8):666\u201372.","journal-title":"Am J Addict"},{"issue":"11","key":"1168_CR129","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.euroneuro.2017.08.435","volume":"27","author":"C Skoglund","year":"2017","unstructured":"Skoglund C, et al. Methylphenidate doses in attention deficit\/hyperactivity disorder and comorbid substance use disorders. Eur Neuropsychopharmacol. 2017;27(11):1144\u201352.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1168_CR130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12888-015-0657-9","volume":"15","author":"XM Barkla","year":"2015","unstructured":"Barkla XM, McArdle PA, Newbury-Birch D. Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature. BMC Psychiatry. 2015;15:270.","journal-title":"BMC Psychiatry"},{"issue":"2","key":"1168_CR131","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ajad.12660","volume":"27","author":"CA Brezing","year":"2018","unstructured":"Brezing CA, et al. Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Am J Addict. 2018;27(2):101\u20137.","journal-title":"Am J Addict"},{"key":"1168_CR132","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108765","volume":"225","author":"FR Levin","year":"2021","unstructured":"Levin FR, et al. Non-abstinent treatment outcomes for cannabis use disorder. Drug Alcohol Depend. 2021;225: 108765.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"1168_CR133","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1530-0277.2007.00403.x","volume":"31","author":"KA Bradley","year":"2007","unstructured":"Bradley KA, et al. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208\u201317.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"1168_CR134","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0306-4603(82)90005-3","volume":"7","author":"HA Skinner","year":"1982","unstructured":"Skinner HA. The drug abuse screening test. Addict Behav. 1982;7(4):363\u201371.","journal-title":"Addict Behav"},{"issue":"1","key":"1168_CR135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mcna.2021.08.002","volume":"106","author":"J McNeely","year":"2022","unstructured":"McNeely J, Hamilton L. Screening for unhealthy alcohol and drug use in general medicine settings. Med Clin North Am. 2022;106(1):13\u201328.","journal-title":"Med Clin North Am"},{"key":"1168_CR136","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40814-015-0001-7","volume":"1","author":"J Birch","year":"2015","unstructured":"Birch J, et al. A pilot feasibility trial of alcohol screening and brief intervention in the police custody setting (ACCEPT): study protocol for a cluster randomised controlled trial. Pilot Feasibility Stud. 2015;1:6.","journal-title":"Pilot Feasibility Stud"},{"issue":"10","key":"1168_CR137","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.JAA.0000795888.70937.34","volume":"31","author":"Q Jones","year":"2018","unstructured":"Jones Q, et al. Implementing standardized substance use disorder screening in primary care. JAAPA. 2018;31(10):42\u20135.","journal-title":"JAAPA"},{"issue":"5","key":"1168_CR138","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.10721","volume":"4","author":"J McNeely","year":"2021","unstructured":"McNeely J, et al. Comparison of methods for alcohol and drug screening in primary care clinics. JAMA Netw Open. 2021;4(5): e2110721.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1168_CR139","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/00912174221106826","volume":"58","author":"D Adamis","year":"2023","unstructured":"Adamis D, et al. Prevalence of attention deficit hyperactivity disorder in an adult mental health service in the Republic of Ireland. Int J Psychiatry Med. 2023;58(2):130\u201344.","journal-title":"Int J Psychiatry Med"},{"key":"1168_CR140","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114524","volume":"311","author":"DE Babinski","year":"2022","unstructured":"Babinski DE, et al. Screening for ADHD in a general outpatient psychiatric sample of adults. Psychiatry Res. 2022;311: 114524.","journal-title":"Psychiatry Res"},{"key":"1168_CR141","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2021.106924","volume":"119","author":"A Looby","year":"2021","unstructured":"Looby A, et al. Relations among protective behavioral strategies, biological sex, and ADHD symptoms on alcohol use and related problems: who benefits most, and from what type of strategy? Addict Behav. 2021;119: 106924.","journal-title":"Addict Behav"},{"issue":"5","key":"1168_CR142","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.beth.2021.01.007","volume":"52","author":"LE Oddo","year":"2021","unstructured":"Oddo LE, et al. Enhanced brief motivational intervention for college student drinkers with ADHD: goal-directed activation as a mechanism of change. Behav Ther. 2021;52(5):1198\u2013212.","journal-title":"Behav Ther"},{"key":"1168_CR143","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108201","volume":"215","author":"S Carreiro","year":"2020","unstructured":"Carreiro S, et al. Current reporting of usability and impact of mHealth interventions for substance use disorder: a systematic review. Drug Alcohol Depend. 2020;215: 108201.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1168_CR144","doi-asserted-by":"crossref","DOI":"10.2196\/10899","volume":"7","author":"T Song","year":"2019","unstructured":"Song T, Qian S, Yu P. Mobile health interventions for self-control of unhealthy alcohol use: systematic review. JMIR Mhealth Uhealth. 2019;7(1): e10899.","journal-title":"JMIR Mhealth Uhealth"},{"issue":"4","key":"1168_CR145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1087054712459885","volume":"19","author":"M Rooney","year":"2015","unstructured":"Rooney M, Chronis-Tuscano AM, Huggins S. Disinhibition mediates the relationship between ADHD and problematic alcohol use in college students. J Atten Disord. 2015;19(4):313\u201327.","journal-title":"J Atten Disord"},{"issue":"24","key":"1168_CR146","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.2174\/0929867323666161202092908","volume":"24","author":"R Agabio","year":"2017","unstructured":"Agabio R, et al. Sex differences in alcohol use disorder. Curr Med Chem. 2017;24(24):2661\u201370.","journal-title":"Curr Med Chem"},{"issue":"4","key":"1168_CR147","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.4088\/JCP.14m09630","volume":"77","author":"S Cortese","year":"2016","unstructured":"Cortese S, et al. Gender differences in adult attention-deficit\/hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry. 2016;77(4):e421\u20138.","journal-title":"J Clin Psychiatry"},{"key":"1168_CR148","doi-asserted-by":"crossref","unstructured":"Castellano-Garcia F et al. Sex differences in substance use, prevalence, pharmacological therapy, and mental health in adolescents with attention-deficit\/hyperactivity disorder (ADHD). Brain Sci. 2022;12(5).","DOI":"10.3390\/brainsci12050590"},{"key":"1168_CR149","doi-asserted-by":"crossref","unstructured":"Tebeka S et al. Changes in alcohol use and heavy episodic drinking in U.S. women of childbearing-age and peripartum between 2001\u20132002 and 2012\u20132013. Addict Behav. 2020;107:106389.","DOI":"10.1016\/j.addbeh.2020.106389"},{"issue":"2","key":"1168_CR150","first-page":"08","volume":"40","author":"BS McCrady","year":"2020","unstructured":"McCrady BS, Epstein EE, Fokas KF. Treatment interventions for women with alcohol use disorder. Alcohol Res. 2020;40(2):08.","journal-title":"Alcohol Res"},{"issue":"4","key":"1168_CR151","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/08404704241229973","volume":"37","author":"H Ross","year":"2024","unstructured":"Ross H, Kurbatfinski S, Szelest I. Investigating the unique service and treatment needs of women with alcohol use disorder: literature review and key informant perspectives in British Columbia. Healthc Manage Forum. 2024;37(4):237\u201343.","journal-title":"Healthc Manage Forum"},{"issue":"1","key":"1168_CR152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/adb0000330","volume":"32","author":"EE Epstein","year":"2018","unstructured":"Epstein EE, et al. A randomized trial of female-specific cognitive behavior therapy for alcohol dependent women. Psychol Addict Behav. 2018;32(1):1\u201315.","journal-title":"Psychol Addict Behav"},{"key":"1168_CR153","doi-asserted-by":"crossref","unstructured":"Griffith AK, Martel MM, Fillmore MT. Effect of menstrual cycle on rewarding properties of alcohol cues in women. Psychol Addict Behav. 2023.","DOI":"10.1037\/adb0000978"},{"issue":"6","key":"1168_CR154","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1037\/adb0000576","volume":"34","author":"J Hayaki","year":"2020","unstructured":"Hayaki J, et al. Menstrual cycle phase, alcohol consumption, alcohol cravings, and mood among women in outpatient treatment for alcohol use disorder. Psychol Addict Behav. 2020;34(6):680\u20139.","journal-title":"Psychol Addict Behav"},{"key":"1168_CR155","doi-asserted-by":"crossref","first-page":"1306194","DOI":"10.3389\/fpsyt.2023.1306194","volume":"14","author":"M de Jong","year":"2023","unstructured":"de Jong M, et al. Female-specific pharmacotherapy in ADHD: premenstrual adjustment of psychostimulant dosage. Front Psychiatry. 2023;14:1306194.","journal-title":"Front Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01168-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01168-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01168-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:18:04Z","timestamp":1744219084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01168-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":155,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01168-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"6 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Mariely Hernandez is a postdoctoral fellow whose salary is funded by the National Institute on Drug Abuse (NIDA; T32DA007294-MPI\u2014Frances R. Levin and Diana Martinez). This research was also supported by a grant from the National Institute on Drug Abuse (5R25DA035161; multiple principle investigators [PIs]: Ruglass and Hien). The funder had no role in the design of the review, in the collection or interpretation of the literature, in the writing of the manuscript, or in the decision to publish the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Drug Abuse.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Levin receives grant support from the NIDA, National Center for Advancing Translational Sciences (NCATS), SAMHSA, and US World Meds and research support from Aelis Pharmaceuticals. She also receives medication from Indivior for research and royalties from APA Publishing. She serves on the National Advisory Council on Alcohol Abuse and Alcoholism. In addition, Dr. Levin served as a nonpaid member of a Scientific Advisory Board for Alkermes, Atai Life Science, Boehringer Ingelheim, Indivior, Novartis, Teva, and US WorldMeds and is a consultant to Major League Baseball. Dr. Hernandez and Dr. Campbell do not have any conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Mariely Hernandez: intellectual content development and writing; Frances R. Levin: conception and development, interpretation of data, critical review, and revisions; and Aimee N.C. Campbell: substantial revisions and critical review. All authors have approved the final version of the manuscript and agree to be accountable for this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}